Nutraceuticals and their preventive or potential therapeutic value in Parkinson's disease

Nutrition Reviews

Volumn 70, Issue 7, 2012, Pages 373-386

  Chao, Jianfei ^a,b   Leung, Yen ^a   Wang, Mingfu ^b   Chang, Raymond Chuen Chung ^a,c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Dietary supplement; Neuroprotection; Nutraceuticals; Parkinson's disease

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; BAICALEIN; CREATINE; CURCUMIN; CURCUMINOID; CYANOCOBALAMIN; EPICATECHIN; EPICATECHIN 3 GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; FOLIC ACID; GENISTEIN; GINSENG EXTRACT; GINSENOSIDE RG 1; HERBACEOUS AGENT; LEVODOPA; NUTRACEUTICAL; OXYRESVERATROL; POLYPHENOL; PYRIDOXINE; RESVERATROL; TETRAHYDROCURCUMIN; UBIDECARENONE; UNCLASSIFIED DRUG; UNSATURATED FATTY ACID; VITAMIN D;

ANTIOXIDANT ACTIVITY; ARTICLE; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HYPERHOMOCYSTEINEMIA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; TEA;

EID: 84863314750     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2012.00484.x     Document Type: Article

References (133)

1. Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003;18:19-31.
2. Frigerio R, Sanft KR, Grossardt BR, etal. Chemical exposures and Parkinson's disease: a population-based case-control study. Mov Disord. 2006;21:1688-1692.
3. Ascherio A, Chen H, Weisskopf MG, etal. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006;60:197-203.
4. Cicchetti F, Lapointe N, Roberge-Tremblay A, etal. Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats. Neurobiol Dis. 2005;20:360-371.
5. Fahn S. Parkinson's disease: 10 years of progress, 1997-2007. Mov Disord. 2010;25(Suppl 1):S2-S14.
6. Schapira AH, Agid Y, Barone P, etal. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur J Neurol. 2009;16:1090-1099.
7. Forloni G, Terreni L, Bertani I, etal. Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol Aging. 2002;23:957-976.
8. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol. 2007;6:352-361.
9. Rubinsztein DC. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature. 2006;443:780-786.
10. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97:1634-1658.
11. Youdim MB, Riederer P. Understanding Parkinson's disease. Sci Am. 1997;276:52-59.
12. Castellani RJ, Perry G, Siedlak SL, etal. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett. 2002;319:25-28.
13. Sudha K, Rao AV, Rao S, etal. Free radical toxicity and antioxidants in Parkinson's disease. Neurol India. 2003;51:60-62.
14. Perier C, Bove J, Wu DC, etal. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proc Natl Acad Sci U S A. 2007;104:8161-8166.
15. Beal MF. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci. 2003;91:120-131.
16. Hartmann A, Hunot S, Michel PP, etal. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A. 2000;97:2875-2880.
17. Langston JW, Ballard P, Tetrud JW, etal. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
18. Reichmann H, Janetzky B. Mitochondrial dysfunction - a pathogenetic factor in Parkinson's disease. J Neurol. 2000;247(Suppl 2):II63-II68.
19. Lambert AJ, Brand MD. Reactive oxygen species production by mitochondria. Methods Mol Biol. 2009;554:165-181.
20. Emborg ME. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neurosci Methods. 2004;139:121-143.
21. Liu J, Ames BN. Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer's disease, and Parkinson's disease. Nutr Neurosci. 2005;8:67-89.
22. Khrapko K, Vijg J. Mitochondrial DNA mutations and aging: devils in the details? Trends Genet. 2009;25:91-98.
23. Trifunovic A, Larsson NG. Mitochondrial dysfunction as a cause of ageing. J Intern Med. 2008;263:167-178.
24. Fato R, Bergamini C, Leoni S, etal. Generation of reactive oxygen species by mitochondrial complex I: implications in neurodegeneration. Neurochem Res. 2008;33:2487-2501.
25. Chaturvedi RK, Shukla S, Seth K, etal. Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Neurobiol Dis. 2006;22:421-434.
26. Maxwell SRJ. Antioxidant vitamin supplements: update of their potential benefits and possible risks. Drug Saf. 1999;21:253-266.
27. Anderson C, Checkoway H, Franklin GM, etal. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. 1999;14:21-27.
28. Fahn S. An open trial of high-dosage antioxidants in early Parkinson's disease. Am J Clin Nutr. 1991;53:S380-S382.
29. Martin A, Youdim K, Szprengiel A, etal. Roles of vitamins E and C on neurodegenerative diseases and cognitive performance. Nutr Rev. 2002;60:308-326.
30. The Parkinson Study Group Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993;328:176-183.
31. Olanow CW. Dietary vitamin E and Parkinson's disease: something to chew on. Lancet Neurol. 2003;2:74.
32. Zhang SM, Hernan MA, Chen H, etal. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology. 2002;59:1161-1169.
33. Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 2005;4:362-365.
34. Scheider WL, Hershey LA, Vena JE, etal. Dietary antioxidants and other dietary factors in the etiology of Parkinson's disease. Mov Disord. 1997;12:190-196.
35. Verhagen H, Buijsse B, Jansen E, etal. The state of antioxidant affairs. Nutr Today. 2006;41:244-250.
36. Newmark HL, Newmark J. Vitamin D and Parkinson's disease - a hypothesis. Mov Disord. 2007;22:461-468.
37. Wang JY, Wu JN, Cherng TL, etal. Vitamin D attenuates 6-hydroxydopamine-induced neurotoxicity 3 in rats. Brain Res. 2001;904:67-75.
38. Shinpo K, Kikuchi S, Sasaki H, etal. Effect of 1, 25-dihydroxyvitamin D3 on cultured mesencephalic dopaminergic neurons to the combined toxicity caused by L-buthionine sulfoximine and 1-methyl-4-phenylpyridine. J Neurosci Res. 2000;62:374-382.
39. Zhang J, Sokal I, Peskind ER, etal. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Clin Chem. 2008;129:526-529.
40. Knekt P, Kilkkinen A, Rissanen H, etal. Serum vitamin D and the risk of Parkinson disease. Arch Neurol. 2010;67:808-811.
41. Kirik D, Georgievska B, Rosenblad C, etal. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci. 2001;13:1589-1599.
42. Garcion E, Wion-Barbot N, Montero-Menei CN, etal. New clues about vitamin D functions in the nervous system. Trends Endocrinol Metab. 2002;13:100-105.
43. Evatt ML, Delong MR, Khazai N, etal. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348-1352.
44. Shults CW. Therapeutic role of coenzyme Q(10) in Parkinson's disease. Pharmacol Ther. 2005;107:120-130.
45. Beal MF, Matthews RT, Tieleman A, etal. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1, 2, 3, tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice. Brain Res. 1998;783:109-114.
46. Cleren C, Yang L, Lorenzo B, etal. Therapeutic effects of coenzyme Q10 (CoQ10) and reduced CoQ10 in the MPTP model of Parkinsonism. J Neurochem. 2008;104:1613-1621.
47. Shults CW, Oakes D, Kieburtz K, etal. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.
48. Muller T, Buttner T, Gholipour AF, etal. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett. 2003;341:201-204.
49. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005;72:1065-1070.
50. Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. Biofactors. 1999;9:267-272.
51. Matthews RT, Ferrante RJ, Klivenyi P, etal. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142-149.
52. Bender A, Koch W, Elstner M, etal. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67:1262-1264.
53. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat Disord. 2009;15(Suppl 3):S189-S194.
54. Valastro B, Dekundy A, Danysz W, etal. Oral creatine supplementation attenuates L-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned rats. Behav Brain Res. 2009;197:90-96.
55. de Lau LM, Bornebroek M, Witteman JC, etal. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam Study. Neurology. 2005;64:2040-2045.
56. Chen H, Zhang SM, Hernan MA, etal. Dietary intakes of fat and risk of Parkinson's disease. Am J Epidemiol. 2003;157:1007-1014.
57. Bousquet M, Saint-Pierre M, Julien C, etal. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008;22:1213-1225.
58. Fernstrom JD. Can nutrient supplements modify brain function? Am J Clin Nutr. 2000;71:S1669-S1675.
59. Kris-Etherton PM, Pearson TA, Wan Y, etal. High-monounsaturated fatty acid diets lower both plasma cholesterol and triacylglycerol concentrations. Am J Clin Nutr. 1999;70:1009-1015.
60. Garcia-Arencibia M, Garcia C, Fernandez-Ruiz J. Cannabinoids and Parkinson's disease. CNS Neurol Disord Drug Targets. 2009;8:432-439.
61. Julien C, Berthiaume L, Hadj-Tahar A, etal. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys. Neurochem Int. 2006;48:404-414.
62. Manyam BV. Paralysis agitans and levodopa in "Ayurveda": ancient Indian medical treatise. Mov Disord. 1990;5:47-48.
63. Manyam BV, Sanchez-Ramos JR. Traditional and complementary therapies in Parkinson's disease. Adv Neurol. 1999;80:565-574.
64. Vaidya AB, Rajagopalan TG, Mankodi NA, etal. Treatment of Parkinson's disease with the cowhage plant -Mucuna pruriens Bak. Neurol India. 1978;26:171-176.
65. Nagashayana N, Sankarankutty P, Nampoothiri MR, etal. Association of L-dopa with recovery following Ayurveda medication in Parkinson's disease. J Neurol Sci. 2000;176:124-127.
66. HP200 in Parkinson's Disease Study Group. An alternative medicine treatment for Parkinson's disease: results of a multicenter clinical trial. J Altern Complement Med. 1995;1:249-255.
67. Katzenschlager R, Evans A, Manson A, etal. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75:1672-1677.
68. Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18:706-712.
69. Tharakan B, Dhanasekaran M, Mize-Berge J, etal. Anti-Parkinson botanical Mucuna pruriens prevents levodopa induced plasmid and genomic DNA damage. Phytother Res. 2007;21:1124-1126.
70. Spencer JP, Jenner A, Aruoma OI, etal. Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett. 1994;353:246-250.
71. Urquiaga I, Leighton F. Plant polyphenol antioxidants and oxidative stress. Biol Res. 2000;33:55-64.
72. Pan T, Jankovic J, Le W. Potential therapeutic properties of green tea polyphenols in Parkinson's disease. Drugs Aging. 2003;20:711-721.
73. Mandel S, Weinreb O, Amit T, etal. Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (-)-epigallocatechin-3-gallate: implications for neurodegenerative diseases. J Neurochem. 2004;88:1555-1569.
74. Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutr Biochem. 2004;15:506-516.
75. Levites Y, Weinreb O, Maor G, etal. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem. 2001;78:1073-1082.
76. Mandel S, Weinreb O, Reznichenko L, etal. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain. J Neural Transm Suppl. 2006;71:249-257.
77. Guo S, Yan J, Yang T, etal. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. Biol Psychiatry. 2007;62:1353-1362.
78. Tan LC, Koh WP, Yuan JM, etal. Differential effects of black versus green tea on risk of Parkinson's disease in the Singapore Chinese Health Study. Am J Epidemiol. 2008;167:553-560.
79. Jagatha B, Mythri RB, Vali S, etal. Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med. 2008;44:907-917.
80. Zbarsky V, Datla KP, Parkar S, etal. Neuroprotective properties of the natural phenolic antioxidants curcumin and naringenin but not quercetin and fisetin in a 6-OHDA model of Parkinson's disease. Free Radic Res. 2005;39:1119-1125.
81. Wang J, Du XX, Jiang H, etal. Curcumin attenuates 6-hydroxydopamine-induced cytotoxicity by anti-oxidation and nuclear factor-kappa B modulation in MES23.5 cells. Biochem Pharmacol. 2009;78:178-183.
82. Yang S, Zhang D, Yang Z, etal. Curcumin protects dopaminergic neuron against LPS induced neurotoxicity in primary rat neuron/glia culture. Neurochem Res. 2008;33:2044-2053.
83. Yu S, Zheng W, Xin N, etal. Curcumin prevents dopaminergic neuronal death through inhibition of the c-Jun N-terminal kinase pathway. Rejuvenation Res. 2010;13:55-64.
84. Chen J, Tang XQ, Zhi JL, etal. Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis. 2006;11:943-953.
85. Rajeswari A, Sabesan M. Inhibition of monoamine oxidase-B by the polyphenolic compound, curcumin and its metabolite tetrahydrocurcumin, in a model of Parkinson's disease induced by MPTP neurodegeneration in mice. Inflammopharmacology. 2008;16:96-99.
86. Wang MS, Boddapati S, Emadi S, etal. Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci. 2010;11:57.
87. Pandey N, Strider J, Nolan WC, etal. Curcumin inhibits aggregation of alpha-synuclein. Acta Neuropathol. 2008;115:479-489.
88. Ortiz-Ortiz MA, Moran JM, Bravosanpedro JM, etal. Curcumin enhances paraquat-induced apoptosis of N27 mesencephalic cells via the generation of reactive oxygen species. Neurotoxicology. 2009;30:1008-1018.
89. Ortiz-Ortiz MA, Moran JM, Ruiz-Mesa LM, etal. Curcumin exposure induces expression of the Parkinson's disease-associated leucine-rich repeat kinase 2 (LRRK2) in rat mesencephalic cells. Neurosci Lett. 2010;468:120-124.
90. van Leyen K, Kim HY, Lee SR, etal. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke. 2006;37:3014-3018.
91. Chen SF, Hsu CW, Huang WH, etal. Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. Br J Pharmacol. 2008;155:1279-1296.
92. Cheng Y, He G, Mu X, etal. Neuroprotective effect of baicalein against MPTP neurotoxicity: behavioral, biochemical and immunohistochemical profile. Neurosci Lett. 2008;441:16-20.
93. Mu X, He G, Cheng Y, etal. Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro. Pharmacol Biochem Behav. 2009;92:642-648.
94. Waxman EA, Emmer KL, Giasson BI. Residue Glu83 plays a major role in negatively regulating a-synuclein amyloid formation. Biochem Bioph Res Commun. 2010;391:1415-1420.
95. Jiang M, Porat-Shliom Y, Pei Z, etal. Baicalein reduces E46K alpha-synuclein aggregation in vitro and protects cells against E46K alpha-synuclein toxicity in cell models of familiar Parkinsonism. J Neurochem. 2010;114:419-429.
96. Fremont L. Biological effects of resveratrol. Life Sci. 2000;66:663-673.
97. Burns J, Yokota T, Ashihara H, etal. Plant foods and herbal sources of resveratrol. J Agric Food Chem. 2002;50:3337-3340.
98. Bhat KPL, Kosmeder JW, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3:1041-1064.
99. Zhang F, Shi JS, Zhou H, etal. Resveratrol protects dopamine neurons against lipopolysaccharide-induced neurotoxicity through its anti-inflammatory actions. Mol Pharmacol. 2010;78:466-477.
100. Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and quercetin against MPP+ -induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. Cell Mol Neurobiol. 2009;29:1169-1180.
101. Lee MK, Kang SJ, Poncz M, etal. Resveratrol protects SH-SY5Y neuroblastoma cells from apoptosis induced by dopamine. Exp Mol Med. 2007;39:376-384.
102. Lu KT, Ko MC, Chen BY, etal. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem. 2008;56:6910-6913.
103. Khan MM, Ahmad A, Ishrat T, etal. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010;1328:139-151.
104. Bureau G, Longpre F, Martinoli MG. Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation. J Neurosci Res. 2008;86:403-410.
105. Albani D, Polito L, Batelli S, etal. The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem. 2009;110:1445-1456.
106. Pallas M, Verdaguer E, Tajes M, etal. Modulation of sirtuins: new targets for antiageing. Recent Pat CNS Drug Discov. 2008;3:61-69.
107. Pallas M, Casadesus G, Smith MA, etal. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathway towards neuroprotection. Curr Neurovasc Res. 2009;6:70-81.
108. Fang SC, Hsu CL, Yen GC. Anti-inflammatory effects of phenolic compounds isolated from the fruits of Artocarpus heterophyllus. J Agric Food Chem. 2008;56:4463-4468.
109. Su BN, Cuendet M, Hawthorne ME, etal. Constituents of the bark and twigs of Artocarpus dadah with cyclooxygenase inhibitory activity. J Nat Prod. 2002;65:163-169.
110. Jeon SY, Kwon SH, Seong YH, etal. Beta-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine. 2007;14:403-408.
111. Chao J, Yu MS, Ho YS, etal. Dietary oxyresveratrol prevents parkinsonian mimetic 6-hydroxydopamine neurotoxicity. Free Radic Biol Med. 2008;45:1019-1026.
112. Xu L, Chen WF, Wong MS. Ginsenoside Rg1 protects dopaminergic neurons in a rat model of Parkinson's disease through the IGF-I receptor signalling pathway. Br J Pharmacol. 2009;158:738-748.
113. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, etal. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp Neurol. 2010;224:517-526.
114. Sawada H, Shimohama S. Estrogens and Parkinson disease: novel approach for neuroprotection. Endocrine. 2003;21:77-79.
115. Chen XC, Zhou YC, Chen Y, etal. Ginsenoside Rg1 reduces MPTP-induced substantia nigra neuron loss by suppressing oxidative stress. Acta Pharmacol Sin. 2005;26:56-62.
116. Ma ZC, Gao Y, Wang YG, etal. Ginsenoside Rg1 inhibits proliferation of vascular smooth muscle cells stimulated by tumor necrosis factor-alpha. Acta Pharmacol Sin. 2006;27:1000-1006.
117. Leung KW, Yung KKL, Mak NK, etal. Neuroprotective effects of ginsenoside-Rg1 in primary nigral neurons against rotenone toxicity. Neuropharmacology. 2007;52:827-835.
118. Gao QG, Chen WF, Xie JX, etal. Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways. J Neurochem. 2009;109:1338-1347.
119. Ge KL, Chen WF, Xie JX, etal. Ginsenoside Rg1 protects against 6-OHDA-induced toxicity in MES23.5 cells via Akt and ERK signaling pathways. J Ethnopharmacol. 2010;127:118-123.
120. +-treated MES23.5 cells via attenuating DMT1 up-regulation and cellular iron uptake. Neuropharmacology. 2010;58:488-494.
121. Leppa S, Bohmann D. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis. Oncogene. 1999;18:6158-6162.
122. Wang J, Xu HM, Yang HD, etal. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins. Neurochem Int. 2009;54:43-48.
123. Ma Y, Sullivan JC, Schreihofer DA. Dietary genistein and equol (4′, 7 isoflavandiol) reduce oxidative stress and protect rats against focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010;299:R871-R877.
124. Azadbakht L, Kimiagar M, Mehrabi Y, etal. Dietary soya intake alters plasma antioxidant status and lipid peroxidation in postmenopausal women with the metabolic syndrome. Br J Nutr. 2007;98:807-813.
125. Cyr M, Calon F, Morissette M, etal. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J Psychiatry Neurosci. 2002;27:12-27.
126. Baluchnejadmojarad T, Roghani M, Nadoushan JMR, etal. Neuroprotective effect of genistein in 6-hydroxydopamine hemi-parkinsonian rat model. Phytother Res. 2009;23:132-135.
127. Huang YH, Zhang ZQ. Genistein reduced the neural apoptosis in the brain of ovariectomised rats by modulating mitochondrial oxidative stress. Br J Nutr. 2010;104:1-7.
128. Kaul S, Anantharam V, Yang Y, etal. Tyrosine phosphorylation regulates the proteolytic activation of protein kinase C in dopaminergic neuronal cells. J Biol Chem. 2005;280:28721-28730.
129. Miller JW, Selhub J, Nadeau MR, etal. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60:1125-1129.
130. Zesiewicz TA, Wecker L, Sullivan KL, etal. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol. 2006;29:106-111.
131. Lamberti P, Zoccolella S, Armenise E, etal. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration. Eur J Neurol. 2005;12:365-368.
132. Nagayama H, Hamamoto M, Ueda M, etal. The effect of ascorbic acid on the pharmacokinetics of levodopa in elderly patients with Parkinson disease. Clin Neuropharmacol. 2004;27:270-273.
133. Fernandez N, Carriedo D, Sierra M, etal. Hydrosoluble fiber (Plantago ovata husk) and levodopa II: experimental study of the pharmacokinetic interaction in the presence of carbidopa. Eur Neuropsychopharmacol. 2005;15:505-509.